Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate

Hagop M. Kantarjian, Susan O'Brien, Jorge E. Cortes, Terry L. Smith, Mary Beth Rios, Jianqin Shan, Ying Yang, Francis J. Giles, Deborah A. Thomas, Stefan Faderl, Guillermo Garcia-Manero, Sima Jeha, William Wierda, Jean Pierre J. Issa, Steven M. Kornblau, Michael Keating, Debra Resta, Renaud Capdeville, Moshe Talpaz

Research output: Contribution to journalArticle

Abstract

Purpose: Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML). Experimental Design: We treated 237 patients (median age, 50 years; age range, 18-82 years) with Philadelphia chromosome (Ph)-positive accelerated-phase CML with oral imatinib mesylate at daily doses of 400 mg (26 patients) or 600 mg (211 patients) and evaluated response and survival characteristics in univariate and multivariate analyses. Results: Among the 200 patients with accelerated-phase CML for whom follow-up was 3 months or more, rates of complete and partial hematological response were 80% and 10%. Cytogenetic responses were evident in 90 patients [45%; complete response in 47 patients (24%) and partial response (Ph 1-34%) in 21 patients (11%)]. The estimated 18-month survival rate was 73%. The estimated complete hematological response rate at 18 months was 68%; that for cytogenetic response was 82%. In multivariate analyses, a diagnosis-to-treatment interval of 3 years or more, splenomegaly, and peripheral blasts predicted poor major cytogenetic response; age >60 years, marrow basophilia, and clonal evolution predicted poor survival. The 600-mg drug dose was associated with better cytogenetic response and survival in univariate analysis (P < 0.01) but not in multivariate analysis. Landmark analysis showed that achieving a cytogenetic response at 3 months or a major cytogenetic response (Ph < 35%) at 6 months was associated with better long-term survival. Seven of 15 patients who were in a second chronic phase achieved major cytogenetic response. The incidence of severe nonhematological toxic effects was 23%; drug discontinuation for severe toxicity was needed in 3% of patients. Conclusions: Imatinib mesylate was active against Ph-positive, accelerated-phase CML, and the prognostic factors identified in this study could aid in tailoring treatment strategies to specific risk groups.

Original languageEnglish (US)
Pages (from-to)2167-2176
Number of pages10
JournalClinical Cancer Research
Volume8
Issue number7
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Philadelphia Chromosome
Cytogenetics
Therapeutics
Survival
Multivariate Analysis
bcr-abl Fusion Proteins
Clonal Evolution
Imatinib Mesylate
Poisons
Splenomegaly
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pharmaceutical Preparations
Research Design
Survival Rate
Bone Marrow

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kantarjian, H. M., O'Brien, S., Cortes, J. E., Smith, T. L., Rios, M. B., Shan, J., ... Talpaz, M. (2002). Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clinical Cancer Research, 8(7), 2167-2176.

Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. / Kantarjian, Hagop M.; O'Brien, Susan; Cortes, Jorge E.; Smith, Terry L.; Rios, Mary Beth; Shan, Jianqin; Yang, Ying; Giles, Francis J.; Thomas, Deborah A.; Faderl, Stefan; Garcia-Manero, Guillermo; Jeha, Sima; Wierda, William; Issa, Jean Pierre J.; Kornblau, Steven M.; Keating, Michael; Resta, Debra; Capdeville, Renaud; Talpaz, Moshe.

In: Clinical Cancer Research, Vol. 8, No. 7, 01.01.2002, p. 2167-2176.

Research output: Contribution to journalArticle

Kantarjian, HM, O'Brien, S, Cortes, JE, Smith, TL, Rios, MB, Shan, J, Yang, Y, Giles, FJ, Thomas, DA, Faderl, S, Garcia-Manero, G, Jeha, S, Wierda, W, Issa, JPJ, Kornblau, SM, Keating, M, Resta, D, Capdeville, R & Talpaz, M 2002, 'Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate', Clinical Cancer Research, vol. 8, no. 7, pp. 2167-2176.
Kantarjian, Hagop M. ; O'Brien, Susan ; Cortes, Jorge E. ; Smith, Terry L. ; Rios, Mary Beth ; Shan, Jianqin ; Yang, Ying ; Giles, Francis J. ; Thomas, Deborah A. ; Faderl, Stefan ; Garcia-Manero, Guillermo ; Jeha, Sima ; Wierda, William ; Issa, Jean Pierre J. ; Kornblau, Steven M. ; Keating, Michael ; Resta, Debra ; Capdeville, Renaud ; Talpaz, Moshe. / Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 7. pp. 2167-2176.
@article{216b2f25b4df4771aa28e8d03f6d3cb2,
title = "Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate",
abstract = "Purpose: Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML). Experimental Design: We treated 237 patients (median age, 50 years; age range, 18-82 years) with Philadelphia chromosome (Ph)-positive accelerated-phase CML with oral imatinib mesylate at daily doses of 400 mg (26 patients) or 600 mg (211 patients) and evaluated response and survival characteristics in univariate and multivariate analyses. Results: Among the 200 patients with accelerated-phase CML for whom follow-up was 3 months or more, rates of complete and partial hematological response were 80{\%} and 10{\%}. Cytogenetic responses were evident in 90 patients [45{\%}; complete response in 47 patients (24{\%}) and partial response (Ph 1-34{\%}) in 21 patients (11{\%})]. The estimated 18-month survival rate was 73{\%}. The estimated complete hematological response rate at 18 months was 68{\%}; that for cytogenetic response was 82{\%}. In multivariate analyses, a diagnosis-to-treatment interval of 3 years or more, splenomegaly, and peripheral blasts predicted poor major cytogenetic response; age >60 years, marrow basophilia, and clonal evolution predicted poor survival. The 600-mg drug dose was associated with better cytogenetic response and survival in univariate analysis (P < 0.01) but not in multivariate analysis. Landmark analysis showed that achieving a cytogenetic response at 3 months or a major cytogenetic response (Ph < 35{\%}) at 6 months was associated with better long-term survival. Seven of 15 patients who were in a second chronic phase achieved major cytogenetic response. The incidence of severe nonhematological toxic effects was 23{\%}; drug discontinuation for severe toxicity was needed in 3{\%} of patients. Conclusions: Imatinib mesylate was active against Ph-positive, accelerated-phase CML, and the prognostic factors identified in this study could aid in tailoring treatment strategies to specific risk groups.",
author = "Kantarjian, {Hagop M.} and Susan O'Brien and Cortes, {Jorge E.} and Smith, {Terry L.} and Rios, {Mary Beth} and Jianqin Shan and Ying Yang and Giles, {Francis J.} and Thomas, {Deborah A.} and Stefan Faderl and Guillermo Garcia-Manero and Sima Jeha and William Wierda and Issa, {Jean Pierre J.} and Kornblau, {Steven M.} and Michael Keating and Debra Resta and Renaud Capdeville and Moshe Talpaz",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "8",
pages = "2167--2176",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate

AU - Kantarjian, Hagop M.

AU - O'Brien, Susan

AU - Cortes, Jorge E.

AU - Smith, Terry L.

AU - Rios, Mary Beth

AU - Shan, Jianqin

AU - Yang, Ying

AU - Giles, Francis J.

AU - Thomas, Deborah A.

AU - Faderl, Stefan

AU - Garcia-Manero, Guillermo

AU - Jeha, Sima

AU - Wierda, William

AU - Issa, Jean Pierre J.

AU - Kornblau, Steven M.

AU - Keating, Michael

AU - Resta, Debra

AU - Capdeville, Renaud

AU - Talpaz, Moshe

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Purpose: Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML). Experimental Design: We treated 237 patients (median age, 50 years; age range, 18-82 years) with Philadelphia chromosome (Ph)-positive accelerated-phase CML with oral imatinib mesylate at daily doses of 400 mg (26 patients) or 600 mg (211 patients) and evaluated response and survival characteristics in univariate and multivariate analyses. Results: Among the 200 patients with accelerated-phase CML for whom follow-up was 3 months or more, rates of complete and partial hematological response were 80% and 10%. Cytogenetic responses were evident in 90 patients [45%; complete response in 47 patients (24%) and partial response (Ph 1-34%) in 21 patients (11%)]. The estimated 18-month survival rate was 73%. The estimated complete hematological response rate at 18 months was 68%; that for cytogenetic response was 82%. In multivariate analyses, a diagnosis-to-treatment interval of 3 years or more, splenomegaly, and peripheral blasts predicted poor major cytogenetic response; age >60 years, marrow basophilia, and clonal evolution predicted poor survival. The 600-mg drug dose was associated with better cytogenetic response and survival in univariate analysis (P < 0.01) but not in multivariate analysis. Landmark analysis showed that achieving a cytogenetic response at 3 months or a major cytogenetic response (Ph < 35%) at 6 months was associated with better long-term survival. Seven of 15 patients who were in a second chronic phase achieved major cytogenetic response. The incidence of severe nonhematological toxic effects was 23%; drug discontinuation for severe toxicity was needed in 3% of patients. Conclusions: Imatinib mesylate was active against Ph-positive, accelerated-phase CML, and the prognostic factors identified in this study could aid in tailoring treatment strategies to specific risk groups.

AB - Purpose: Imatinib mesylate, a specific Bcr-Abl tyrosine kinase inhibitor, has shown encouraging activity in chronic myelogenous leukemia (CML). Experimental Design: We treated 237 patients (median age, 50 years; age range, 18-82 years) with Philadelphia chromosome (Ph)-positive accelerated-phase CML with oral imatinib mesylate at daily doses of 400 mg (26 patients) or 600 mg (211 patients) and evaluated response and survival characteristics in univariate and multivariate analyses. Results: Among the 200 patients with accelerated-phase CML for whom follow-up was 3 months or more, rates of complete and partial hematological response were 80% and 10%. Cytogenetic responses were evident in 90 patients [45%; complete response in 47 patients (24%) and partial response (Ph 1-34%) in 21 patients (11%)]. The estimated 18-month survival rate was 73%. The estimated complete hematological response rate at 18 months was 68%; that for cytogenetic response was 82%. In multivariate analyses, a diagnosis-to-treatment interval of 3 years or more, splenomegaly, and peripheral blasts predicted poor major cytogenetic response; age >60 years, marrow basophilia, and clonal evolution predicted poor survival. The 600-mg drug dose was associated with better cytogenetic response and survival in univariate analysis (P < 0.01) but not in multivariate analysis. Landmark analysis showed that achieving a cytogenetic response at 3 months or a major cytogenetic response (Ph < 35%) at 6 months was associated with better long-term survival. Seven of 15 patients who were in a second chronic phase achieved major cytogenetic response. The incidence of severe nonhematological toxic effects was 23%; drug discontinuation for severe toxicity was needed in 3% of patients. Conclusions: Imatinib mesylate was active against Ph-positive, accelerated-phase CML, and the prognostic factors identified in this study could aid in tailoring treatment strategies to specific risk groups.

UR - http://www.scopus.com/inward/record.url?scp=0035992318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035992318&partnerID=8YFLogxK

M3 - Article

C2 - 12114417

AN - SCOPUS:0035992318

VL - 8

SP - 2167

EP - 2176

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -